116 related articles for article (PubMed ID: 27852036)
21. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
[TBL] [Abstract][Full Text] [Related]
22. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
Jaffee EM; Hruban RH; Biedrzycki B; Laheru D; Schepers K; Sauter PR; Goemann M; Coleman J; Grochow L; Donehower RC; Lillemoe KD; O'Reilly S; Abrams RA; Pardoll DM; Cameron JL; Yeo CJ
J Clin Oncol; 2001 Jan; 19(1):145-56. PubMed ID: 11134207
[TBL] [Abstract][Full Text] [Related]
23. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
24. Continuous low-dose GM-CSF as salvage therapy in refractory recurrent breast or female genital tract carcinoma.
Kurbacher CM; Kurbacher JA; Cramer EM; Rhiem K; Mallman PK; Reichelt R; Reinhold U; Stier U; Cree IA
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):23-6. PubMed ID: 15934497
[TBL] [Abstract][Full Text] [Related]
25. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
26. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.
Mahvi DM; Sondel PM; Yang NS; Albertini MR; Schiller JH; Hank J; Heiner J; Gan J; Swain W; Logrono R
Hum Gene Ther; 1997 May; 8(7):875-91. PubMed ID: 9143914
[TBL] [Abstract][Full Text] [Related]
27. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
[TBL] [Abstract][Full Text] [Related]
29. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
Mahvi DM; Shi FS; Yang NS; Weber S; Hank J; Albertini M; Schiller J; Schalch H; Larson M; Pharo L; Gan J; Heisey D; Warner T; Sondel PM
Hum Gene Ther; 2002 Sep; 13(14):1711-21. PubMed ID: 12396624
[TBL] [Abstract][Full Text] [Related]
30. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.
Feyerabend S; Stevanovic S; Gouttefangeas C; Wernet D; Hennenlotter J; Bedke J; Dietz K; Pascolo S; Kuczyk M; Rammensee HG; Stenzl A
Prostate; 2009 Jun; 69(9):917-27. PubMed ID: 19267352
[TBL] [Abstract][Full Text] [Related]
31. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
32. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
[TBL] [Abstract][Full Text] [Related]
33. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
34. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
36. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
37. The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
Ripley D; Tang XM; Ma C; Chegini N
Gynecol Oncol; 2001 May; 81(2):301-9. PubMed ID: 11330966
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
Roche MR; Rudd PJ; Krasner CN; Matulonis UA; Berlin ST; Lee H; Silver M; Tran CD; Seiden MV; Penson RT
Gynecol Oncol; 2010 Feb; 116(2):168-72. PubMed ID: 19922985
[TBL] [Abstract][Full Text] [Related]
39. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
40. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
